About Ali Behbahani
Ali Behbahani is a director and 10% owner at Black Diamond Therapeutics.
Form D filings name Ali Behbahani as a director at SpyGlassPharma and 858 Therapeutics.
Ali Behbahani reports to the SEC as a director or major shareholder of 23 public companies, including CRISPR Therapeutics AG (CRSP), Monte Rosa Therapeutics (GLUE) and Korro Bio (KRRO).
Ali Behbahani first appears on SEC filings in 2014.
Experience
This experience comes from SEC filings. The years are when the filings name Ali Behbahani in the role, so the role may have started earlier or lasted longer.
BI
Black Diamond Therapeutics, Inc.
Director and 10% owner
2020 – 2026 · Public company (BDTX)
CA
CRISPR Therapeutics AG
Director
2016 – 2026 · Public company (CRSP)
MI
Monte Rosa Therapeutics, Inc.
Director and 10% owner
2021 – 2026 · Public company (GLUE)
KI
Korro Bio, Inc.
Director and 10% owner
2023 – 2026 · Public company (KRRO)
NI
Nkarta, Inc.
Director
2020 – 2026 · Public company (NKTX)
AI
Arcellx, Inc.
Director
2022 – 2026 · Public company (ACLX)
TI
Trevi Therapeutics, Inc.
10% owner
2019 – 2026 · Public company (TRVI)
NI
NeueHealth, Inc.
Director and 10% owner
2021 – 2025 · Public company (NEUE)
AP
Adaptimmune Therapeutics PLC
Director
2016 – 2025 · Public company (ADAP)
MI
Marker Therapeutics, Inc.
Director and 10% owner
2018 – 2024 · Public company (MRKR)
MI
MBX Biosciences, Inc.
10% owner
2024 · Public company (MBX)
CI
CVRx, Inc.
Director
2021 – 2024 · Public company (CVRX)
SI
Savara Inc
10% owner
2021 – 2023 · Public company (SVRA)
MI
Mirum Pharmaceuticals, Inc.
10% owner
2019 – 2023 · Public company (MIRM)
OI
Oyster Point Pharma, Inc.
Director
2019 – 2023 · Public company (OYST)
AI
Akouos, Inc.
10% owner
2020 – 2022 · Public company (AKUS)
MI
Minerva Surgical Inc.
Director
2021 – 2022 · Public company (UTRS)
GI
Genocea Biosciences, Inc.
Director and 10% owner
2018 – 2022 · Public company (GNCA)
MI
Metacrine, Inc.
10% owner
2020 – 2021 · Public company (MTCR)
RI
Regulus Therapeutics Inc.
10% owner
2018 – 2021 · Public company (RGLS)
XI
X4 Pharmaceuticals, Inc
10% owner
2018 · Public company (XFOR)
NC
Nevro Corp.
Director
2014 – 2018 · Public company (NVRO)
Key Colleagues at Startups
The people Ali Behbahani works with at each company, as listed on that company's latest Form D.
SpyGlassPharma, Inc. · Form D, Jun 5, 2025
JM
Jake Merrill
Director
MK
Malik Kahook
Executive officer and director
GP
Geoff Pardo
Director
BK
Bilal Khan
Director
CY
Cynthia Yee
Director
RZ
Roger Zhang
Director
PM
Patrick Mooney
Chief Executive Officer and director
ZS
Zach Scheiner
Director
858 Therapeutics, Inc. · Form D, Jul 11, 2024
JV
James Veal
Executive officer
JH
Jane Huang
Director
MM
Monal Mehta
Director
SJ
Stafford Jeffrey
Executive officer and director
KM
Katherine Bell-McGuinn
Executive officer
CO
Clare Ozawa
Director